-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1767 Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical Research, CML, Chronic Myeloid Malignancies, Diseases, Real-world evidence, Adverse Events, Myeloid Malignancies
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Mengyao Yuan1*, Li Zhou, MD2*, Xin Du, PhD3, Jianyu Weng, MD, PhD4*, Linhua Yang5*, Yanping Ma5*, Shasha Zhao6*, Zhenfang Liu, MD7*, Qin Wen, MD8*, Qingxian Bai9*, Xianqi Feng10*, Yanqiu Han11*, Aifang Li12*, Chunshui Liu13*, Qing Leng14*, Li Meng, MD15*, Baohong Wang, MD16*, Xuehong Ran, MD16*, Xiaodong Wang17*, Haiguo Zhang18*, Yun Zeng19*, Yanli Zhang, MD20* and Qian Jiang, MD21

1Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China, Beijing, China
2Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, West Roxbury, MA
3Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, WA, China
4Guangdong Provincial People's Hospital, Guangdong, China
5Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China
6Peking University People’s Hospital, Qingdao, China
7The First Affiliated Hospital of Guangxi Medical University, Nanning, China
8Xinqiao Hospital, Army Medical University, Chongqing, China
9Xijing Hospital, Air Force Medical University, Xi'An, China
10Department of Hematology, The Affiliated Hospital of Qingdao University, qingdao, China
11The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
12Baoshan People's Hospital, Baoshan, China
13Department of Hematology, The First Hospital of Jilin University, Changchun, China
14Anshan Central Hospital, Anshan, China
15Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
16Department of Hematology, Weifang People's Hospital, Weifang, CHN
17Department of Hematology, Sichuan Academy of Medical Sciences Sichuan Provincial, Sichuan, CHN
18Jining NO.1 People's Hospital, Jining, CHN
19Department of Hematology, First Affiliated Hospital of Kunming Medical Universit, Kuming, CHN
20Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
21Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Background Olverembatinib is a novel 3G-TKI, which has shown efficacy and safety in patients with CML-CP or CML-AP harboring T315I mutation, resistance or intolerance to imatinib or 2G-TKI. However, there are limited data on olverembatinib-therapy in patients with CML-AP.

Objectives To retrospectively analyze efficacy and safety and explore co-variates associated with outcomes of olverembatinib to classify patients into risk cohorts to predict progression-free survival (PFS) and survival in patients with CML-AP.

Methods We collected data of CML-AP patients receiving olverembatinib from university hospitals or academic centers in China. CML-AP was diagnosed according to ELN 2020 criteria. Cumulative incidences of MCyR, CCyR, MMR and MR4 were calculated using the Fine-Gray test considering competing events defined as a transplant or death. PFS and survival were calculated by Kaplan-Meier method. X-tile plots were used to determine optimal cut-off value continuous co-variates. Multi-variable Cox regression analyses were used to explore co-variates associated with outcomes on olverembatinib.

Results Eighty-nine patients with CML-AP receiving olverembatinib from 19 centers were included. Forty-six (52%) were from clinical trials; 43 (48%), from real world post marketing. Twenty-one (24%) was newly diagnosed CML-AP and 68 (76%) transformed from CML-CP to CML-AP. Sixty-six (74%) were male. Median age at the start of olverembatinib was 44 (Interquartile range [IQR], 34-58) years. Median interval from CML diagnosis to olverembatinib was 6.2 (IQR, 2.3-10.2) years. Thirty-six (40%) patients had ≥ 1 comorbidity(ies). 39 (44%) had 2 prior TKIs; 38 (43%), ≥ 3 prior TKIs. BCR::ABL1 mutation detected by Sanger sequencing prior to olverembatinib was available for 86 patients: 44 (51%) harbored a single T315I mutation; 16 (19%), T315I plus additional mutations; 12 (14%), other mutations; 14 (16%), no mutation.

Five (6%) patients received oral olverembatinib at alternate-day (QOD) dose of 20 mg; 19 (21%), 30 mg QOD; 58 (65%), 40 mg QOD; 7 (8%), 50 mg QOD. Median follow-up was 23 (IQR, 5-62) months. Among 42 patients with no MaHR at baseline, 25 (60%) achieved MaHR and CHR within 3 months. 5-year cumulative incidences of MCyR, CCyR, MMR and MR4.0 were 49% (95% CI: 36, 63%]), 49% (36, 62%), 49% (36, 62%) and 39% (26, 53%), respectively. 22 patients progressed to AP again or blast phase, 19 died of disease progression (n = 15, 79%), cardiovascular events (CVEs) (n = 2, 10%), coronavirus disease 2019 (n = 1, 5%) or unknown (n = 1, 5%). 5-year probabilities of PFS and OS were 65% (54, 79%) and 65% (54, 80%), respectively.

In multi-variable analyses haemoglobin < 117 g/L (Hazard ratio [HR] = 5.2 [1.8, 14.8], p = 0.002), blood basophils ≥ 9% (HR = 3.6 [1.3, 9.6], p = 0.011) and additional cytogenetic abnormalities (ACAs) in Ph+ cells (HR = 4.0 [1.8, 10.1], p = 0.004) at baseline were significantly-associated with worse PFS. Comorbidity(ies) (HR = 3.0 [1.1, 8.2], p = 0.038) and blood basophils ≥ 8% (HR = 4.1 [1.4, 12.1], p = 0.010) at baseline were significantly-associated with worse survival. Based on number of baseline adverse prognostic co-variates, patients were classified into the low- (none, n = 18, 24%), intermediate- (one or two, n = 51, 69%) and high-risk (three, n = 5, 7%) cohorts with significant difference in PFS (p < 0.001) with 5-year PFS rates of 100% (100, 100%), 59% (45, 78%) and 0, respectively; the low- (≤ one, n = 69, 85%) and high-risk (two, n = 12, 15%) cohorts with significant difference in survival (p = 0.001) with 5-year survival rates of 73% (61, 87%) and 0.

Seventy-three (82%) patients experienced at least 1 treatment-related adverse events (TRAE). Thirty-three (37%) developed grade 3/4 hematological TRAE including leucopenia (n = 18, 20%) and thrombocytopenia (n = 33, 37%). The most common nonhematologic TRAE was skin hyperpigmentation in 48 (55%) patients, followed by hypertriglyceridemia (42%) and hypocalcaemia (36%). CVEs were observed in 19 (23%) patients including hypertension (14%), sinus tachycardia (6%), pericardial effusion (5%), cerebral infarction or atrial fibrillation (2% each), and myocardial infarction (1%).

Conclusions Olverembatinib is an effective 3G-TKI with well tolerance in patients with CML-AP. Anemia, increasing blood basophils and ACAs in Ph+ cells at baseline were significantly-associated with worse PFS; comorbidity(ies) and increasing blood basophils, worse survival.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH